Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions

Eur J Pharmacol. 2024 Dec 15:985:177110. doi: 10.1016/j.ejphar.2024.177110. Epub 2024 Nov 14.

Abstract

Hypertension remains a critical global health issue, despite significant advancements in treatment, management and preventive approaches. Current antihypertensive drugs have limitations, such as low adherence, renin-angiotensin-aldosterone system reactivation, and drug resistance,. Ongoing preclinical and clinical studies for siRNA therapies show promising results, demonstrating significant blood pressure reductions and their potential as effective, durable treatments. This narrative review explores the potential of siRNA therapies in transforming hypertension management covering the literature until May 2024 and offering a precision medicine approach. We searched various databases, including PubMed, http://www.clinicaltrial.gov, and www.Espacenet.com, using 'hypertension' and 'siRNA' as the main keywords to retrieve relevant studies. The impact of these therapies could be profound, offering improved efficacy, reduced side effects, and enhanced patient adherence. As research continues to validate their safety and effectiveness, siRNA therapies may become integral components of hypertension management.

Publication types

  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents* / pharmacology
  • Antihypertensive Agents* / therapeutic use
  • Blood Pressure / drug effects
  • Humans
  • Hypertension* / genetics
  • Hypertension* / therapy
  • RNA, Small Interfering* / therapeutic use

Substances

  • RNA, Small Interfering
  • Antihypertensive Agents